Syndrome of inappropriate ADH secretion, now often referred to as syndrome of inappropriate antidiuresis, is a disorder of water and electrolyte regulation in which the action of arginine vasopressin (AVP, historically called ADH) remains unsuppressed despite reduced plasma osmolality. The final effect is retention of free water mediated by V2 receptors in the collecting duct, with development of hypo-osmolality and hyponatremia, typically in a clinical context of apparent euvolemia, in which expansion of the extracellular compartment is modest and is counterbalanced by natriuresis and hormonal adaptations.
Unlike hyponatremia due to volume depletion, in which AVP is an appropriate signal to defend perfusion, in SIADH antidiuresis is uncoupled from physiological need and becomes a pathological driver. The clinical phenotype depends mainly on the rapidity of onset and the depth of hyponatremia: an acute reduction in sodium may cause cerebral edema with severe neurological manifestations, whereas in chronic forms subtler but clinically relevant signs predominate, such as postural instability, attentional deficits and increased risk of falls.
Hyponatremia is the most common electrolyte disorder in clinical practice, and SIADH is one of the most frequent causes of hypotonic hyponatremia, especially in the hospital setting. Its epidemiological importance does not derive only from its frequency, but also from the fact that it often occurs in frail or critically ill patients, in whom hyponatremia is associated with increased length of hospital stay, complications and mortality, even when it is not the only determinant of outcome. In this context, SIADH should be interpreted as a pathophysiological signal of non-osmotic activation of the vasopressin system, often sustained by acute diseases, medications or neoplasms.
From the perspective of risk factors, SIADH typically emerges in three major clinical scenarios. The first is the oncological setting, in which some neoplasms may produce ectopic AVP or persistently stimulate vasopressin secretion; the classic association is with small-cell lung carcinoma, but other neoplasms and anticancer treatments may also contribute. The second scenario is the pulmonary setting, in which infections, mechanical ventilation, hypoxia and parenchymal diseases activate non-osmotic pathways that promote AVP release, making hyponatremia an epiphenomenon of significant respiratory disease. The third is the neurological setting, which includes central nervous system disorders such as hemorrhage, infections, trauma and neoplasms, capable of directly altering the osmotic set point or activating vasopressin secretion through stress pathways.
Alongside these scenarios, a central role is played by medications. Many agents can induce SIADH by increasing AVP secretion, potentiating its renal action or interfering with dilution mechanisms. The groups most often involved include serotonergic antidepressants, antipsychotics, anticonvulsants, some chemotherapeutic agents and medications that increase renal sensitivity to AVP. Susceptibility is higher in older people, in individuals with comorbidities and in patients with low solute intake, because free water excretion also depends on the ability to generate an adequate urinary osmotic load.
A further predisposing factor, often underestimated, is the context of low solute intake and reduced capacity to eliminate free water. Even when AVP is only moderately increased, the combination of antidiuresis and low urinary osmotic load can stabilize persistent hyponatremia. In practice, SIADH is not a monolithic condition, but a point of convergence for multiple factors that increase the vasopressin signal or amplify its effect, making clinical assessment essential to identify both the causes and the predisposing context.
The pathophysiology of SIADH is centered on the action of AVP on V2 receptors in the collecting duct. Under physiological conditions, a reduction in plasma osmolality suppresses AVP and allows the production of dilute urine, eliminating free water until osmolality is restored. In SIADH this circuit is interrupted: AVP remains present or the kidney behaves as if the signal were present, maintaining aquaporin-2 on the apical membrane of principal cells and reducing free water excretion. The retained water dilutes plasma sodium and lowers osmolality, generating hypotonic hyponatremia.
The etiology includes forms due to non-osmotic secretion of AVP and forms of inappropriate antidiuresis in which the problem is predominantly renal or receptor-mediated. Non-osmotic secretion may be mediated by nausea, pain, stress, hypoxia and medications, or sustained by neurological and pulmonary diseases that activate central circuits of vasopressin release. In neoplasms, ectopic production of AVP or related peptides may generate a persistent and relatively autonomous signal. In some cases, the pathophysiology may include a reset osmostat, in which the threshold for AVP secretion is shifted toward lower osmolality values, stabilizing moderate chronic hyponatremia that may be clinically insidious.
A distinctive feature of SIADH is that water retention causes only modest expansion of extracellular volume, because the body responds by activating compensatory mechanisms. The increase in effective volume suppresses the renin angiotensin aldosterone system and stimulates natriuresis, helping to maintain a picture of apparent euvolemia. This response explains why hyponatremia may persist even in the absence of edema and why urine, in many cases, shows relatively high sodium: natriuresis is part of the adaptation to water expansion, not a sign of volume loss.
The extent of the disorder is determined not only by AVP levels, but also by the kidney’s ability to generate dilute urine, which depends on solute load and the integrity of the diluting segment. When the available osmotic load is low, the maximum amount of water that can be eliminated is reduced and hyponatremia becomes more likely even with moderate levels of antidiuresis. This principle is crucial for understanding why some patients develop severe hyponatremia with non-extreme AVP levels, and why intervention on solute balance may have a therapeutic role in selected chronic forms.
At the neurological level, the pathogenesis of symptoms derives from the reduction in extracellular osmolality, which promotes water shift into the intracellular compartment and may cause cerebral edema. In acute forms, the brain’s adaptive capacity is limited and the risk of herniation increases when sodium falls rapidly. In chronic forms, by contrast, the brain reduces intracellular osmoles to protect itself from edema, but this adaptation makes overly rapid correction dangerous because it exposes the patient to the risk of osmotic demyelination syndrome. SIADH is therefore a condition in which pathophysiology requires not only correction of sodium, but correction through a time strategy consistent with cerebral adaptation.
The clinical presentation of SIADH is determined by the combination of sodium level and rate of reduction. In the history, in acute or rapidly progressive forms, the patient may report nausea, vomiting, headache, unsteadiness, confusion and, in the most severe cases, seizures. These symptoms reflect cerebral edema and neurological distress due to hypotonic hyponatremia. In the hospital setting, onset may be subtle and present as worsening mental status, agitation or drowsiness in a patient with a concomitant acute illness.
In chronic forms, especially when sodium decreases slowly, symptoms may be more subtle and often incorrectly attributed to other conditions. Asthenia, reduced attention, psychomotor slowing, balance disorders and increased risk of falls are frequent, particularly in older people. In this group, even moderate hyponatremia can have a significant clinical impact, because it alters cognitive and neuromuscular functions in a nonspecific but relevant way for prognosis and autonomy.
On physical examination, SIADH is typically associated with a picture of apparent euvolemia, without edema, without signs of congestion and without evidence of volume depletion such as marked orthostatic hypotension or very dry mucous membranes. However, clinical assessment of volemia is not always straightforward and may be confounded by comorbidities, age and concomitant therapies. For this reason, clinical findings must be integrated with laboratory data and etiological context, avoiding reliance on a single sign for diagnosis.
In patients with pulmonary or neurological disease, the symptoms of SIADH may overlap with those of the underlying condition, making a pathophysiological interpretation essential. The presence of unexplained neurological worsening, persistent nausea, reduced level of consciousness or seizures in a patient with hyponatremia must always prompt consideration of the hypo-osmolar component as a potential contributing cause and indicate urgent management according to protocols for symptomatic hyponatremia.
Finally, SIADH may present as incidental hyponatremia in asymptomatic patients, especially in chronic forms. In these cases, the syndrome remains clinically relevant because it exposes the patient to risk in the event of procedures, hypotonic infusions, changes in water intake and additional medications. Even the absence of obvious symptoms does not exclude an impact on fall risk, frailty and overall clinical course, especially when the underlying cause is severe or progressive.
Suspicion of SIADH should arise in the presence of hypotonic hyponatremia in a patient without signs of edema and without clinical evidence of volume depletion, especially when the urine is inappropriately concentrated. It is essential to begin by confirming that the hyponatremia is true and hypotonic, because pseudohyponatremia or hypertonic hyponatremia require a different pathway. Once the hypotonic context has been defined, the combination of low plasma osmolality and inability to produce adequately dilute urine points toward water retention mediated by AVP or equivalent mechanisms.
Suspicion becomes particularly strong when, in the presence of hyponatremia, urinary osmolality remains above the expected values for an organism that should suppress AVP. In parallel, the presence of relatively high urinary sodium in a patient without recent diuretic therapy and with apparent euvolemia suggests that natriuresis is part of the adaptation to water expansion, consistent with the pathophysiology of SIADH. In these cases, the diagnosis should not be made before excluding alternative causes of euvolemic hyponatremia, particularly adrenal insufficiency and significant hypothyroidism, because both can mimic or promote a similar phenotype.
Suspicion should be highest in the presence of typical triggers: neoplasms, pulmonary infections, acute neurological diseases, persistent nausea, pain, surgical stress and use of medications known to promote inappropriate antidiuresis. In a hospitalized patient, a fall in sodium after introduction of a new medication, after a neurological event or during pneumonia should prompt targeted evaluation, because correction of the triggering factor may be as important as sodium therapy.
Another situation in which SIADH should be suspected is moderate chronic hyponatremia without obvious signs, especially in older patients with instability, falls or cognitive worsening. In this scenario, SIADH may be sustained by polypharmacy or by subclinical chronic diseases. Suspicion is clinically important because sodium management and medication review may reduce the risk of falls and complications, even when hyponatremia does not appear dramatic.
Finally, suspicion of SIADH must include awareness that clinical euvolemia is an imperfect assessment. In the presence of uncertainty, the diagnostic pathway must be based on osmolality, urine studies, exclusion of endocrine causes and evaluation of the context, avoiding shortcuts that may lead to inappropriate treatments, such as unnecessary administration of hypotonic solutions or failure to provide urgent correction in symptomatic cases.
The diagnosis of SIADH is based on a rational pathway that demonstrates: hypotonic hyponatremia, inappropriate antidiuresis and absence of other causes that justify the picture. The first step is to confirm the hypotonic nature of hyponatremia by measuring plasma osmolality, since conditions such as hyperglycemia or the presence of effective osmoles may reduce measured sodium without reflecting an excess of free water. In parallel, clinical severity must be assessed with attention to neurological symptoms, because the degree of therapeutic urgency depends on symptoms as well as on the absolute sodium value.
The second step is urinary analysis. In an individual who should suppress AVP, urinary osmolality should be very low. In SIADH, however, urine is inappropriately concentrated relative to low plasma osmolality, because V2 action maintains water permeability in the collecting duct. Urinary sodium is often elevated or not reduced, consistent with natriuresis due to water expansion and suppression of the renin angiotensin aldosterone system, but interpretation must take diet, infusions and therapies into account.
An essential step is exclusion of adrenal insufficiency and clinically significant hypothyroidism, because both can cause hyponatremia with similar features. Evaluation should include morning cortisol and, if necessary, dynamic tests, as well as thyroid-stimulating hormone (TSH) and free thyroxine (FT4), interpreted consistently with the clinical context. The presence of diuretics, especially thiazides, can confound the picture and must be considered carefully, because it alters dilution capacity and may mimic a euvolemic form of hyponatremia with high urinary sodium.
In practice, the diagnosis of SIADH is strengthened by demonstration of an euvolemic picture, low plasma osmolality, non-suppressed urinary osmolality and absence of alternative causes. Measurement of copeptin may be useful in specialized pathways, but in SIADH the variability of AVP and copeptin levels in relation to stress, nausea and comorbidities makes integrated assessment more important than a single biomarker. In complex cases, response to treatment and serial reassessment of sodium, osmolality and urinary parameters may help consolidate the diagnosis and avoid classification errors.
Once the diagnosis has been made, the cause must be identified. This requires a careful medication history, clinical and radiological evaluation for pulmonary and neurological diseases, and investigation for neoplasms when the context suggests it. The objective is not only to label SIADH, but to define the mechanism and trigger, because the most effective management often derives from removal or treatment of the underlying cause in addition to corrective sodium measures.
The clinical classification of SIADH is useful for defining urgency and therapeutic strategy. A first fundamental axis distinguishes acute hyponatremia from chronic hyponatremia, because cerebral adaptation completely changes the risk profile. In acute forms, lack of adaptation exposes the patient to cerebral edema and rapid neurological complications. In chronic forms, adaptation protects against edema but increases the risk of injury from overly rapid correction, making a cautious and controlled strategy necessary.
A second axis concerns clinical severity based on symptoms. The presence of seizures, major impairment of mental status or signs of intracranial hypertension requires emergent management of hyponatremia, regardless of cause, because the immediate risk is neurological. In the absence of severe symptoms, the strategy may be more gradual and oriented toward sustainable correction and etiological treatment. This distinction is crucial because the same sodium concentration may be tolerated very differently depending on the speed of onset and the patient’s neurological reserve.
A third axis considers pathophysiological mechanisms within SIADH. In some patients persistent AVP secretion predominates, in others a reset of the osmotic set point stabilizes chronically reduced but relatively stable sodium, and in still others antidiuresis is amplified by low solute intake or renal factors that limit dilution. This variability explains why some forms respond well to water restriction, whereas others require second-line strategies, such as increasing free water excretion with loop diuretics, urea or V2 antagonists in selected settings.
Finally, a practical classification distinguishes transient from persistent SIADH. SIADH related to acute nausea, pain or medications may resolve with removal of the trigger, whereas forms associated with neoplasms or chronic diseases may persist and require a long-term management plan. This distinction has implications for follow-up and for the choice of sustainable therapies, because the goal is not merely to correct a laboratory value, but to stabilize the patient by reducing recurrences and complications.
Treatment of SIADH must integrate two objectives: safely managing hyponatremia and addressing the underlying cause when possible. The first decision concerns the presence of moderate or severe neurological symptoms, because in that case the priority is to reduce the risk of cerebral edema through timely and controlled correction with hypertonic saline, according to protocols that use boluses or infusions guided by initial sodium increment targets and close monitoring. Emergency management requires frequent sodium measurements and attention to the risk of overcorrection, especially if sudden aquaresis occurs due to resolution of the trigger or concomitant therapeutic interventions.
In patients without severe symptoms, the most common initial strategy is water restriction, which aims to make water intake lower than the residual capacity for free water excretion. Efficacy depends on urinary osmolality and solute load: if urine is highly concentrated, the amount of water that can be eliminated is reduced and restriction must be stricter to be effective, with a practical impact that is often difficult to sustain. In these cases, simple restriction may fail and must be combined with or replaced by strategies that increase free water excretion.
The use of loop diuretics combined with adequate solute intake may reduce urinary concentrating capacity by interfering with the medullary gradient and increasing free water clearance. This approach requires surveillance of electrolyte balance, because it may promote sodium and potassium losses if not properly implemented. A consolidated strategy in selected chronic forms is the use of oral urea, which increases the urinary osmotic load and promotes osmotic diuresis, improving sodium with a profile that, in many contexts, is sustainable in the long term. Controlled increase in protein load may also contribute in selected patients, precisely through an increase in the eliminable osmotic load.
V2 receptor antagonists, such as tolvaptan, increase free water excretion by blocking AVP action and may rapidly correct hyponatremia. Their use, however, requires caution, because the rapidity of response may cause overcorrection, especially in forms with high susceptibility to aquaresis. For this reason, patient selection and sodium monitoring in the first hours and days are decisive. In many practices, vaptans are reserved for selected forms that are resistant to standard measures or have specific clinical indications, balancing efficacy, safety and the local regulatory context.
Regardless of the chosen strategy, an essential principle is prevention of excessively rapid correction, especially in chronic forms or in patients at high risk of osmotic demyelination, such as malnourished patients, people with alcohol use disorder, patients with liver disease or individuals with significant hypokalemia. In these cases, management may include active strategies to control the correction rate, including the possible use of desmopressin in control protocols in expert centers when sudden aquaresis exposes the patient to sodium overshoot. The optimal approach is therefore pathophysiologically guided, safety-oriented and constantly adapted to the evolution of the clinical picture.
Follow-up of SIADH depends on the fact that the syndrome may be transient or persistent and that hyponatremia may easily recur if the trigger remains. In the initial phases, especially during active correction, sodium monitoring must be close and proportionate to severity and to the therapy used. The objective is to avoid both persistence of symptomatic hyponatremia and overcorrection, which may occur when AVP is suddenly suppressed, when the cause is removed or when aquaretic therapies are used.
In chronic patients, follow-up includes periodic assessment of sodium, osmolality and adherence to prescribed measures, with attention to changes in water intake and solute load. The sustainability of water restriction is a real clinical problem: many patients cannot maintain it and develop sodium fluctuations. In these cases, a strategy that increases free water excretion or modifies the osmotic load may be more stable, but requires monitoring to avoid adverse effects and to verify that sodium remains within a safe range.
A central element of follow-up is etiological management. If SIADH is medication-related, therapeutic review and substitution, when possible, often represent the most effective intervention. If it is related to pulmonary or neurological disease, control of the underlying disease may lead to resolution. In cases in which a neoplastic cause is suspected, follow-up must include an appropriate diagnostic pathway, because SIADH may precede other signs of the neoplasm or represent an indicator of disease activity.
The functional dimension of chronic hyponatremia must also be considered during follow-up. Even in the absence of striking symptoms, sodium stabilization may improve balance, attention and fall risk, with an impact on quality of life. For this reason, the therapeutic decision must take into account not only the numerical value, but also the individual risk profile, frailty and comorbidities. In summary, follow-up of SIADH is a dynamic process that integrates electrolyte monitoring, therapy management, review of precipitating factors and surveillance of the underlying cause.
The prognosis of SIADH depends substantially on the underlying cause and on how rapidly hyponatremia is recognized and managed safely. In many transient forms, the electrolyte prognosis is favorable, with complete resolution when the trigger is removed. In persistent forms, especially oncological forms or those related to chronic diseases, SIADH may require long-term management, in which sodium stability and prevention of fluctuations become central clinical objectives.
The most feared complications are neurological. Acute hyponatremia may cause cerebral edema with seizures, coma and risk of death. Even when the form is chronic, hyponatremia is associated with balance disorders, increased risk of falls and fractures, and cognitive deficits that contribute to frailty, especially in older people. These consequences make SIADH clinically relevant even when the patient does not report dramatic symptoms.
A critical iatrogenic complication is osmotic demyelination syndrome, which may occur when sodium correction is too rapid, especially in chronic hyponatremia or in patients with risk factors such as malnutrition, alcohol use disorder, liver disease and hypokalemia. Demyelination may cause dysarthria, dysphagia, tetraparesis, pseudobulbar syndromes and, in severe cases, locked-in syndrome. This complication is the main reason why SIADH management must be guided not only by the need to increase sodium, but also by the speed and predictability of correction.
Another relevant complication is recurrence. If the cause persists, sodium may fall again rapidly after therapy withdrawal or after changes in water intake. This risk is particularly evident in patients discharged from hospital without a follow-up plan and without medication review. For this reason, functional prognosis improves when management integrates identification of the trigger, patient education and electrolyte monitoring proportionate to risk.
In conclusion, SIADH is a syndrome of high clinical relevance not only because of its frequency, but also because of its potential neurological complications and the need for pathophysiologically coherent therapeutic strategies. The electrolyte prognosis is often favorable if the cause is reversible and if correction is conducted in a controlled manner, whereas global prognosis remains strongly influenced by the underlying etiology.